Becton, Dickinson & Co. buy gerihouse
Zusammenfassung
Diese Einschätzung wurde am 26.01.15 mit einem Endkurs von 126,07 € beendet. Aufwärts ging es für die BUY Einschätzung von gerihouse mit einer Rendite von 10,80 %. gerihouse hat 50% Zuversicht bei dieser EinschätzungBD (Becton, Dickinson and Company) ist ein global tätiges Medizintechnologie-Unternehmen mit Hauptsitz in den USA. Das Unternehmen beschäftigt weltweit über 70.000 Mitarbeiter und ist in den Bereichen Medizintechnik, Diagnostik und Life-Science-Research tätig. Die Produktpalette von BD umfasst unter anderem Spritzen, Infusionssets, Kanülen, Testsysteme und Diagnostikgeräte. BD ist an der New Yorker Börse unter dem Ticker-Symbol BDX gelistet und wurde 1897 gegründet.
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Becton, Dickinson & Co. | -1,55 % | -1,55 % | -9,83 % | 1,88 % |
| iShares Core DAX® | 2,59 % | -1,86 % | 13,24 % | 16,87 % |
| iShares Nasdaq 100 | 3,55 % | -2,06 % | 38,29 % | 45,90 % |
| iShares Nikkei 225® | 0,69 % | -8,70 % | 17,51 % | 2,76 % |
| iShares S&P 500 | 2,21 % | -1,99 % | 27,63 % | 42,95 % |
Kommentare von gerihouse zu dieser Einschätzung
In der Diskussion Becton, Dickinson & Co. diskutieren
Kennt nur eine Richtung
Sehr tolle Medinzintechnik Aktie die kurzfristig ein Hold ist, aber langfristig ein Buy!
Stock analysts at Deutsche Bank raised their price objective on shares of Becton, Dickinson and (NYSE:BDX) from $141.00 to $145.00 in a report issued on Wednesday. The firm currently has a “hold” rating on the stock. Deutsche Bank’s price objective points to a potential upside of 7.62% from the company’s current price.
Shares of Becton, Dickinson and (NYSE:BDX) traded up 4.55% on Wednesday, hitting $140.86. 1,134,341 shares of the company’s stock traded hands. Becton, Dickinson and has a 1-year low of $104.94 and a 1-year high of $135.27. The stock’s 50-day moving average is $127.3 and its 200-day moving average is $119.8. The company has a market cap of $27.022 billion and a P/E ratio of 22.49.
Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.68 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.66 by $0.02. The company had revenue of $2.20 billion for the quarter, compared to the consensus estimate of $2.16 billion. During the same quarter in the prior year, the company posted $1.54 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. On average, analysts predict that Becton, Dickinson and will post $6.80 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, December 31st. Investors of record on Wednesday, December 10th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 1.78%.
A number of other analysts have also recently weighed in on BDX. Analysts at JPMorgan Chase & Co. upgraded shares of Becton, Dickinson and from a “neutral” rating to an “overweight” rating in a research note on Wednesday. They now have a $160.00 price target on the stock, up previously from $134.00. Separately, analysts at Evercore ISI reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Tuesday. They now have a $130.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Becton, Dickinson and in a research note on Wednesday, November 5th. They now have a $133.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $126.64.
Becton Dickinson and Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Beendete Einschätzungen von gerihouse zu Becton, Dickinson & Co.
Becton, Dickinson & Co.
22.02.22
22.02.23
23.02.23
Becton, Dickinson & Co.
18.03.20
04.11.21
05.11.21
Becton, Dickinson & Co.
09.09.16
30.01.17
30.01.17
